0000950170-24-084299.txt : 20240717
0000950170-24-084299.hdr.sgml : 20240717
20240717163012
ACCESSION NUMBER: 0000950170-24-084299
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240715
FILED AS OF DATE: 20240717
DATE AS OF CHANGE: 20240717
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SKYLER JAY S
CENTRAL INDEX KEY: 0001236386
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39871
FILM NUMBER: 241122583
MAIL ADDRESS:
STREET 1: DANCE BIOPHARM INC.
STREET 2: 150 NORTH HILL DRIVE, SUITE 24
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001833214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 853899721
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 W 41ST ST
STREET 2: SUITE 401
CITY: MIAMI BEACH
STATE: FL
ZIP: 33140
BUSINESS PHONE: 305-845-2813
MAIL ADDRESS:
STREET 1: 777 W 41ST ST
STREET 2: SUITE 401
CITY: MIAMI BEACH
STATE: FL
ZIP: 33140
FORMER COMPANY:
FORMER CONFORMED NAME: Big Cypress Acquisition Corp.
DATE OF NAME CHANGE: 20201120
4
1
ownership.xml
4
X0508
4
2024-07-15
0001833214
SAB Biotherapeutics, Inc.
SABS
0001236386
SKYLER JAY S
777 W 41ST ST
SUITE 401
MIAMI BEACH
FL
33140
true
false
false
false
false
Stock Option (right to buy)
2.90
2024-07-15
4
A
false
20000
0
A
2034-07-15
Common Stock
20000
20000
D
Stock Option (right to buy)
2.90
2024-07-15
4
A
false
35000
0
A
2034-07-15
Common Stock
35000
35000
D
Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.
Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on May 3, 2025, 2026, and 2027.
This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
/s/ Jay S. Skyler
2024-07-17